BACKGROUND: We examined the relationship between location of residence at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) and health outcomes in a geographically large Canadian province with publicly funded, universally available medical care. PATIENTS AND METHODS: The British Columbia Cancer Registry was used to identify all patients 18-80 years of age diagnosed with DLBCL between January 2003 and December 2008. Home and treatment center postal codes were used to determine urban versus rural status and driving distance to access treatment. RESULTS: We identified 1,357 patients. The median age was 64 years (range: 18-80 years), 59% were male, 50% were stage III/IV, 84% received chemotherapy with curative intent, and 32% received radiotherapy. There were 186 (14%) who resided in rural areas, 141 (10%) in small urban areas, 183 (14%) in medium urban areas, and 847 (62%) in large urban areas. Patient and treatment characteristics were similar regardless of location. Five-year overall survival (OS) was 62% for patients in rural areas, 44% in small urban areas, 53% in medium urban areas, and 60% in large urban areas (p = .018). In multivariate analysis, there was no difference in OS between rural and large urban area patients (hazard ratio [HR]: 1.0; 95% confidence interval [CI]: 0.7-1.4), although patients in small urban areas (HR: 1.4; 95% CI: 1.0-2.0) and medium urban areas (HR: 1.4; 95% CI: 1.0-1.9) had worse OS than those in large urban areas. CONCLUSION: Place of residence at diagnosis is associated with survival of patients with DLBCL in British Columbia, Canada. Rural patients have similar survival to those in large urban areas, whereas patients living in small and medium urban areas experience worse outcomes.
BACKGROUND: We examined the relationship between location of residence at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) and health outcomes in a geographically large Canadian province with publicly funded, universally available medical care. PATIENTS AND METHODS: The British Columbia Cancer Registry was used to identify all patients 18-80 years of age diagnosed with DLBCL between January 2003 and December 2008. Home and treatment center postal codes were used to determine urban versus rural status and driving distance to access treatment. RESULTS: We identified 1,357 patients. The median age was 64 years (range: 18-80 years), 59% were male, 50% were stage III/IV, 84% received chemotherapy with curative intent, and 32% received radiotherapy. There were 186 (14%) who resided in rural areas, 141 (10%) in small urban areas, 183 (14%) in medium urban areas, and 847 (62%) in large urban areas. Patient and treatment characteristics were similar regardless of location. Five-year overall survival (OS) was 62% for patients in rural areas, 44% in small urban areas, 53% in medium urban areas, and 60% in large urban areas (p = .018). In multivariate analysis, there was no difference in OS between rural and large urban area patients (hazard ratio [HR]: 1.0; 95% confidence interval [CI]: 0.7-1.4), although patients in small urban areas (HR: 1.4; 95% CI: 1.0-2.0) and medium urban areas (HR: 1.4; 95% CI: 1.0-1.9) had worse OS than those in large urban areas. CONCLUSION: Place of residence at diagnosis is associated with survival of patients with DLBCL in British Columbia, Canada. Rural patients have similar survival to those in large urban areas, whereas patients living in small and medium urban areas experience worse outcomes.
Entities:
Keywords:
Access to care; Cancer care quality; Disparities; Lymphoma
Authors: Paul S Craft; John M Buckingham; Jane E Dahlstrom; Kerri R Beckmann; Yanping Zhang; Robin Stuart-Harris; George Jacob; David Roder; Noel Tait Journal: Breast Date: 2010-05-07 Impact factor: 4.380
Authors: Fausto R Loberiza; Mei-Jie Zhang; Stephanie J Lee; John P Klein; Charles F LeMaistre; Derek S Serna; Mary Eapen; Christopher N Bredeson; Mary M Horowitz; J Douglas Rizzo Journal: Blood Date: 2004-12-14 Impact factor: 22.113
Authors: David L Kok; Jiun-Horng Chang; Bircan Erbas; Ashley Fletcher; Anne M Kavanagh; Michael A Henderson; Dorota M Gertig Journal: ANZ J Surg Date: 2006-11 Impact factor: 1.872
Authors: Peter D Baade; Danny R Youlden; Michael D Coory; Robert A Gardiner; Suzanne K Chambers Journal: Med J Aust Date: 2011-03-21 Impact factor: 7.738
Authors: I Magrath; M Adde; A Shad; D Venzon; N Seibel; J Gootenberg; J Neely; C Arndt; M Nieder; E Jaffe; R A Wittes; I D Horak Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: Dragomir Svetozarov Stoyanov; Nikolay Vladimirov Conev; Ivan Shterev Donev; Ivan Dimitrov Tonev; Teodorika Vitalinova Panayotova; Eleonora Georgieva Dimitrova-Gospodinova Journal: Support Care Cancer Date: 2022-03-15 Impact factor: 3.603
Authors: Cécile Borel; Sébastien Lamy; Gisèle Compaci; Christian Récher; Pauline Jeanneau; Jean Claude Nogaro; Eric Bauvin; Fabien Despas; Cyrille Delpierre; Guy Laurent Journal: BMC Cancer Date: 2015-04-15 Impact factor: 4.430
Authors: S Lamy; C Bettiol; P Grosclaude; G Compaci; G Albertus; C Récher; J C Nogaro; F Despas; G Laurent; C Delpierre Journal: BMC Health Serv Res Date: 2016-08-02 Impact factor: 2.655
Authors: Orla M Fitzpatrick; Catherine Murphy; Erica Duignan; Keith Egan; Bryan T Hennessy; Liam Grogan; Adrian Murphy; Oscar S Breathnach; Jarushka Naidoo; Patrick G Morris Journal: Ir J Med Sci Date: 2022-01-17 Impact factor: 2.089